Data from one-year liraglutide phase 3 study published in The Lancet

Novo NordiskData from a 52-week phase 3 study (LEAD™ 3) of liraglutide, a once-daily human GLP-1 analogue, were published by The Lancet. The study showed that liraglutide, when taken alone, produces statistically significant and sustained improvements in blood sugar control in patients with early type 2 diabetes, as compared with glimepiride, a widely used oral antidiabetic drug. Moreover, the treatment with liraglutide leads to weight loss, reduced systolic blood pressure and lower rates of hypoglycaemia after 52 weeks of treatment.

"Publication of this data in The Lancet means that more physicians will have access to these key results on liraglutide's efficacy as monotherapy in the treatment of type 2 diabetes," said principal study investigator Alan Garber, MD, professor of Medicine, Biochemistry & Molecular Biology, and Molecular & Cellular Biology Division of Diabetes, Endocrinology & Metabolism, Baylor College of Medicine, Texas "In addition to effective glycaemic control for at least one year, liraglutide treatment also led to a number of other clinical benefits when given to patients early on in the course of their disease."

Type 2 diabetes is a progressive disease. Many treatments are effective early on in the course of the disease but do not maintain their effectiveness. After 52 weeks of treatment, 62% of treatment-naïve patients treated with liraglutide 1.8 mg achieved an average reduction in blood sugar below the American Diabetes Association target for HbA1c of less than 7% and maintained this reduction over the 52-week study period.

In addition, patients treated with liraglutide had significant weight loss. A mean weight loss of 2.05±4.40 kg and 2.45±4.37 kg occurred with liraglutide 1.2 mg and 1.8 mg, respectively, versus a weight gain of 1.12±4.24 kg with glimepiride.

There were no major hypoglycaemic episodes reported during the study. The rate of minor hypoglycaemia was statistically significantly lower in both liraglutide dose groups compared with the glimepiride-treated group. The most common gastrointestinal-related adverse events were nausea, diarrhea, and vomiting in the liraglutide arms and most were transient.(1) Other adverse events reported included flu-like symptoms.

About Liraglutide
Liraglutide is a once-daily human analogue of the naturally occurring hormone Glucagon-Like Peptide-1 (GLP-1). Liraglutide works by stimulating the release of insulin only when blood sugar levels become too high and by inhibiting appetite. On 23 May 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the United States as well as a marketing authorisation application to the European Medicines Agency in Europe for the approval of liraglutide for the treatment of patients with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on 14 July 2008.

About LEAD™ (Liraglutide Effect and Action in Diabetes)
The data published early online and in an upcoming edition of The Lancet is from the LEAD™ 3 study, one of five randomised, controlled, double-blinded studies that make up the phase 3a programme for liraglutide. The phase 3a programme involved about 4,000 patients with type 2 diabetes in 40 countries.

Data from the LEAD™ 3 study has previously been reported on by Novo Nordisk in a Stock Exchange Announcement on 11 December 2007, and in a press release on 9 June 2008, in connection with the American Diabetes Association meeting in San Francisco.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

Novartis announces plan to initiate clinical trial…

Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the effic...

Gilead announces results from Phase 3 trial of inv…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigation...

AstraZeneca and Oxford University announce landmar…

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine a...

Sanofi and Regeneron provide update on U.S. Phase …

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzar...

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

Loss of smell associated with milder clinical cour…

Following an earlier study that validated the loss of smell and taste as indicators of SARS-CoV-2 infection, researchers at UC San Diego Health report in newly published ...

Can an existing HIV medication slow the spread of …

A team of scientists from St. Michael's Hospital, Sinai Health and Sunnybrook Health Sciences Centre have launched a clinical trial to understand whether an existing drug...